Reply to comment by Suhm N on: Ferrari S, et al. 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO)

Serge Ferrari; Christian Meier

doi:10.57187/smw.2023.40075

Author reply to technical comment

Vol. 153 No. 4 (2023)

Reply to comment by Suhm N on: Ferrari S, et al. 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO)

Serge Ferrari
Christian Meier

DOI: https://doi.org/10.57187/smw.2023.40075
Cite this as:: Swiss Med Wkly. 2023;153:40075
Published: 17.04.2023

Summary

No abstract available.

References

Suhm N. Technical comment on: Ferrari S, et al. 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO): Therapy of osteoporosis in the eldest geriatric patients – a plea for individualized decision-making. Swiss Med Wkly. 2023;153:40074. https://doi.org/10.57187/smw.2023.40074 DOI: https://doi.org/10.57187/smw.2023.40074
Ferrari S, Lippuner K , Lamy O , Meier C . 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO). Swiss Med Wkly. 2020 Sep;150(3940):w20352. https://doi.org/10.4414/smw.2020.20352 DOI: https://doi.org/10.4414/smw.2020.20352
Lyles KW , Colón-Emeric CS , Magaziner JS , Adachi JD , Pieper CF , Mautalen C , et al.; HORIZON Recurrent Fracture Trial . Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 Nov;357(18):1799–809. https://doi.org/10.1056/NEJMoa074941 DOI: https://doi.org/10.1056/NEJMoa074941

How to Cite

1.

Ferrari S, Meier C. Reply to comment by Suhm N on: Ferrari S, et al. 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO). Swiss Med Wkly [Internet]. 2023 Apr. 17 [cited 2024 Apr. 20];153(4):40075. Available from: https://smw.ch/index.php/smw/article/view/3331

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)

Serge Ferrari, Kurt Lippuner, Olivier Lamy, Christian Meier, 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO) , Swiss Medical Weekly: Vol. 150 No. 3940 (2020)
Christian Meier, Brigitte Uebelhart, Bérengère Aubry-Rozier, Martin Birkhäuser, Heike A. Bischoff-Ferrari, Diana Frey, Reto W. Kressig, Olivier Lamy, Kurt Lippuner, Petra Stute, Norbert Suhm, Serge Ferrari, Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the Swiss Association against Osteoporosis (SVGO/ASCO) , Swiss Medical Weekly: Vol. 147 No. 3334 (2017)
Veronika Kreutle, Claudine Blum, Christian Meier, Miriam Past, Beat Müller, Philipp Schütz, Katrin Borm, Bisphosphonate induced hypocalcaemia – report of six cases and review of the literature , Swiss Medical Weekly: Vol. 144 No. 2526 (2014)
Tristan Struja, Alexander Kutz, Stefan Fischli, Christian Meier, Beat Mueller, Philipp Schuetz, Personalised immunomodulating treatments for Graves’ disease: fact or fiction? , Swiss Medical Weekly: Vol. 147 No. 3132 (2017)
Christian Meier, Olivier Lamy, Marc-Antoine Krieg, Hans-Ulrich Mellinghoff, Markus Felder, Serge Ferrari, René Rizzoli, The role of teriparatide in sequential and combination therapy of osteoporosis , Swiss Medical Weekly: Vol. 144 No. 2324 (2014)
Petra Stute, Martin Birkhäuser, Michael von Wolff, Christian Meier, Gynaecologists’ awareness of bone healthcare in Switzerland , Swiss Medical Weekly: Vol. 144 No. 0910 (2014)
Serge Ferrari, Secondary prevention of osteoporotic fractures: Why not apply the evidence? , Swiss Medical Weekly: Vol. 138 No. 4546 (2008)

[1] Suhm N. Technical comment on: Ferrari S, et al. 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO): Therapy of osteoporosis in the eldest geriatric patients – a plea for individualized decision-making. Swiss Med Wkly. 2023;153:40074. https://doi.org/10.57187/smw.2023.40074 DOI: https://doi.org/10.57187/smw.2023.40074

[2] Ferrari S, Lippuner K , Lamy O , Meier C . 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO). Swiss Med Wkly. 2020 Sep;150(3940):w20352. https://doi.org/10.4414/smw.2020.20352 DOI: https://doi.org/10.4414/smw.2020.20352

[3] Lyles KW , Colón-Emeric CS , Magaziner JS , Adachi JD , Pieper CF , Mautalen C , et al.; HORIZON Recurrent Fracture Trial . Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 Nov;357(18):1799–809. https://doi.org/10.1056/NEJMoa074941 DOI: https://doi.org/10.1056/NEJMoa074941